Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Nebivolol on Walking Ability in Patients with Essential Hypertension and Peripheral Arterial Disease (Intermittent Claudication)
2004-004863-32Phase 4Completed
- Sponsor
- Berlin-Chemie AG
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nebivolol in essential hypertension and arteriosclerosis obliterans (2 arms), sponsored by Berlin-Chemie AG. Primary endpoints: Initial claudication distance at 12 weeks and Tolerability of nebivolol versus hydrochlorothiazide. Started Dec 2005; status: completed.
02
Drugs
nebivolol
03
Conditions
essential hypertensionarteriosclerosis obliterans
Beyond the preview
Go deeper on 2004-004863-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004863-32.